Research Group on Quality, Safety and Bioactivity of Plant Foods, CEBAS-CSIC, P.O. Box 164, Murcia 30100, Spain.
Mol Aspects Med. 2010 Dec;31(6):513-39. doi: 10.1016/j.mam.2010.09.005. Epub 2010 Sep 15.
Hydrolysable tannins are phenolic phytochemicals that show high antioxidant and free-radical scavenging activities. For this reason their potential effects preventing oxidative related diseases, such as cardiovascular diseases, have been largely studied. In vitro studies show that ellagitannins, at concentrations in the range 10-100 μM, show some relevant anti-atherogenic, anti-thrombotic, anti-inflammatory and anti-angiogenic effects, supporting the molecular mechanisms for the vascular health benefits. While there is good evidence supporting the vascular effects in vitro, the evidence on animal models or humans is much scarcer. The in vitro results often do not match the findings in the in vivo studies. This could be explained by the low bioavailability of the antioxidant ellagitannins and ellagic acid. The main ellagitannin metabolites circulating in plasma are ellagic acid microbiota metabolites known as urolithins, and they have lost their free-radical scavenging activity. They are present in plasma as glucuronide or sulphate conjugates, at concentrations in the nM range. Future studies should focus in the bioavailable metabolites, urolithins, and in the form (conjugated with glucuronic acid or sulphate) and concentrations (nM range) in which they are found in plasma. In this review we critically discuss the role of ellagitannins and ellagic acid on vascular health.
可水解单宁是具有高抗氧化和自由基清除活性的酚类植物化学物质。因此,它们在预防与氧化相关的疾病(如心血管疾病)方面的潜在作用已被广泛研究。体外研究表明,在 10-100 μM 浓度范围内,鞣花单宁具有一些相关的抗动脉粥样硬化、抗血栓、抗炎和抗血管生成作用,支持其对血管健康有益的分子机制。虽然有充分的证据支持体外的血管作用,但在动物模型或人类中的证据要少得多。体外研究结果通常与体内研究的发现不一致。这可能是由于抗氧化剂鞣花单宁和鞣花酸的生物利用度低所致。循环血浆中的主要鞣花单宁代谢物是微生物群代谢产物的鞣花酸,它们已失去自由基清除活性。它们以葡萄糖醛酸或硫酸盐缀合物的形式存在于血浆中,浓度在纳摩尔范围内。未来的研究应集中在生物可用的代谢物、尿石素上,并关注其在血浆中的存在形式(与葡萄糖醛酸或硫酸盐结合)和浓度(纳摩尔范围)。在这篇综述中,我们批判性地讨论了鞣花单宁和鞣花酸对血管健康的作用。